MY160077A - Curcumin compounds and their preparations thereof - Google Patents

Curcumin compounds and their preparations thereof

Info

Publication number
MY160077A
MY160077A MYPI2011000317A MYPI2011000317A MY160077A MY 160077 A MY160077 A MY 160077A MY PI2011000317 A MYPI2011000317 A MY PI2011000317A MY PI2011000317 A MYPI2011000317 A MY PI2011000317A MY 160077 A MY160077 A MY 160077A
Authority
MY
Malaysia
Prior art keywords
curcumin
compounds
ninhydrin
sarcosine
discloses
Prior art date
Application number
MYPI2011000317A
Inventor
Ismail Rusli
Ashraf Ali Mohamed
Soo Choon Tan
Keng Yoon Yeong
Chee Wei Ang
Suresh Kumar Raju
Osman Hasnah
Original Assignee
Univ Sains Malaysia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Sains Malaysia filed Critical Univ Sains Malaysia
Priority to MYPI2011000317A priority Critical patent/MY160077A/en
Priority to PCT/MY2011/000177 priority patent/WO2012099454A1/en
Publication of MY160077A publication Critical patent/MY160077A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

ACCORDINGLY, THE INVENTION DISCLOSES COMPOUNDS WITH ENHANCED BIOAVAILABILITY FOR THE PREVENTION AND TREATMENT OF ANTI-HUMAN IMMUNODEFICIENCY VIRUS (HIV), ANTI-TUBERCULOSIS (TB), ANTI-ALZHEIMER OR ANTI-CANCER, WITH THE FOLLOWING FORMULAS: THE INVENTION ALSO DISCLOSES THE METHOD IN SYNTHESIZING THESE COMPOUNDS WHEREIN THE STEPS INCLUDES MIXING CURCUMIN, ISATIN DERIVATIVES OR NINHYDRIN AND SARCOSINE OR PHENYL GLYCINE IN 20 ML METHANOL. THE MIXTURE WAS THEN REFLUXED WITH A SOLVENT ON A WATER BATH AND EXCESS SOLVENT WAS REMOVED UNDER VACUUM. THE RESIDUE SUBJECTED TO FLASH COLUMN CHROMATOGRAPHY USING PETROLEUM ETHER: ETHYL ACETATE MIXTURE (4:1) AS ELUENT TO AFFORD THE PRODUCT. THE RATIO FOR CURCUMIN: ISATIN DERIVATIVE/NINHYDRIN: SARCOSINE/PHENYL GLYCINE IS 1:1:2 AND 1:2:4.
MYPI2011000317A 2011-01-21 2011-01-21 Curcumin compounds and their preparations thereof MY160077A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MYPI2011000317A MY160077A (en) 2011-01-21 2011-01-21 Curcumin compounds and their preparations thereof
PCT/MY2011/000177 WO2012099454A1 (en) 2011-01-21 2011-07-22 Curcumin compounds and their preparations thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI2011000317A MY160077A (en) 2011-01-21 2011-01-21 Curcumin compounds and their preparations thereof

Publications (1)

Publication Number Publication Date
MY160077A true MY160077A (en) 2017-02-15

Family

ID=46515925

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2011000317A MY160077A (en) 2011-01-21 2011-01-21 Curcumin compounds and their preparations thereof

Country Status (2)

Country Link
MY (1) MY160077A (en)
WO (1) WO2012099454A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106478491B (en) * 2016-10-08 2019-10-18 贵州大学 3- aminomethyl quaternary carbon Oxoindole splices five yuan of carbocyclic ring loop coil oxidized indole compounds of 3- and preparation method and application
US11352363B1 (en) 2020-11-23 2022-06-07 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2022109363A1 (en) * 2020-11-23 2022-05-27 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US11976084B2 (en) 2020-11-23 2024-05-07 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11384090B2 (en) 2020-11-23 2022-07-12 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11970502B2 (en) 2021-05-04 2024-04-30 Enanta Pharmaceuticals, Inc. Macrocyclic antiviral agents
US11319325B1 (en) 2021-05-11 2022-05-03 Enanta Pharmaceuticals, Inc. Macrocyclic spiropyrrolidine derived antiviral agents
US11339170B1 (en) 2021-07-23 2022-05-24 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11325916B1 (en) 2021-07-29 2022-05-10 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023086352A1 (en) 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US11919910B2 (en) 2021-11-12 2024-03-05 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023086350A1 (en) * 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Alkyne-containing antiviral agents
US11993600B2 (en) 2021-12-08 2024-05-28 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents
CN114057756B (en) * 2021-12-10 2022-12-09 山东第一医科大学(山东省医学科学院) Pyrrolidinyl spiro-oxindole compound with antitumor activity and synthesis method thereof
CN116621918B (en) * 2022-07-20 2023-10-31 深圳信立泰药业股份有限公司 Spiro compound and preparation method and application thereof

Also Published As

Publication number Publication date
WO2012099454A1 (en) 2012-07-26

Similar Documents

Publication Publication Date Title
MY160077A (en) Curcumin compounds and their preparations thereof
NZ705827A (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
WO2015134317A8 (en) Chromatographic materials for the separation of unsaturated molecules
WO2012118812A3 (en) Substituted 6,5-fused bicyclic heteroaryl compounds
MX2011011797A (en) Substituted phenyllureas and phenylamides as vanilloid receptor ligands.
WO2012177844A3 (en) Substituted imidazopyridinyl-aminopyridine compounds
MX2020012596A (en) Processes and intermediates for preparing a medicament.
WO2009005677A3 (en) Antiviral compounds
WO2009005676A3 (en) Antiviral compounds
WO2011081277A3 (en) Saturated n-heterocyclic carbene-ligand metal complex derivatives, preparing method thereof, and preparing method of silane compound by hydrosilylation reaction using the same as catalyst
MX2012002997A (en) Ether derivatives of bicyclic heteroaryls.
WO2012009699A3 (en) Process for preparing antiviral compounds
MX2023011454A (en) Prins reaction and compounds useful in the synthesis of halichondrin macrolides and analogs thereof.
WO2007117591A3 (en) Total synthesis of salinosporamide a and analogs thereof
Zhang et al. Separation and structural elucidation of a new tadalafil analogue diethylaminopretadalafil included as an adulterant in a dietary supplement
WO2012031045A3 (en) Phosphonate ester derivatives and methods of synthesis thereof
MX2018014130A (en) Process and intermediates for the 6,7-alpha-epoxidation of steroid 4,6-dienes.
Cabré et al. Ethylene Glycol Assisted Intermolecular Pauson–Khand Reaction
MX2016010272A (en) Pyrrole-substituted indolone derivative, preparation method therefor, composition comprising same and use thereof.
MX2016001519A (en) 25-oh vitamin d derivatives for determination of vitamin d metabolites.
RU2017107681A (en) Quinazoline derivatives
JP2017513915A5 (en)
Dorn et al. Nickel-catalyzed reductive arylation of activated alkynes with aryl iodides
MY153032A (en) Curcumin compounds with superior structural stability and processes for their preparation thereof
SA517390095B1 (en) Butadiene Telomerization Catalyst and Preparation Thereof